Strata Critical Valuation
| SRTA Stock | 4.50 0.10 2.17% |
At this time, the company appears to be fairly valued. Strata Critical Medical has a current Real Value of USD4.41 per share. The regular price of the company is USD4.5. Our model measures the value of Strata Critical Medical from inspecting the company fundamentals such as Shares Outstanding of 85.13 M, return on equity of -0.24, and Operating Margin of (0.43) % as well as reviewing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Strata Critical's valuation include:
Price Book 1.6904 | Enterprise Value | Enterprise Value Ebitda (9.95) | Price Sales 6.2144 | Enterprise Value Revenue 1.0716 |
Fairly Valued
Today
Please note that Strata Critical's price fluctuation is relatively risky at this time. Calculation of the real value of Strata Critical Medical is based on 3 months time horizon. Increasing Strata Critical's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Strata Critical is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Strata Stock. However, Strata Critical's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 4.5 | Real 4.41 | Hype 4.54 | Naive 4.85 |
The real value of Strata Stock, also known as its intrinsic value, is the underlying worth of Strata Critical Medical Company, which is reflected in its stock price. It is based on Strata Critical's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Strata Critical's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Strata Critical Medical helps investors to forecast how Strata stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Strata Critical more accurately as focusing exclusively on Strata Critical's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Strata Critical's intrinsic value based on its ongoing forecasts of Strata Critical's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Strata Critical's closest peers. If more than one evaluation category is relevant for Strata Critical we suggest using both methods to arrive at a better estimate.
Strata Critical Cash |
|
Strata Revenue by Product
Strata Critical Total Value Analysis
Strata Critical Medical is at this time anticipated to have valuation of 272.55 M with market capitalization of 417.35 M, debt of 9.32 M, and cash on hands of . Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Strata Critical fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
272.55 M | 417.35 M | 9.32 M |
Strata Critical Investor Information
About 69.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.69. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Strata Critical Medical recorded a loss per share of 0.24. The entity had not issued any dividends in recent years. Strata Critical Medical is not in a good financial situation at this time. It has a very high risk of going through financial distress in March.Strata Critical Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Strata Critical has an asset utilization ratio of 96.89 percent. This suggests that the Company is making USD0.97 for each dollar of assets. An increasing asset utilization means that Strata Critical Medical is more efficient with each dollar of assets it utilizes for everyday operations.Strata Critical Profitability Analysis
Taking into consideration Strata Critical's profitability measurements, Strata Critical Medical may not be well positioned to generate adequate gross income at this time. It has a very high risk of underperforming in March. Profitability indicators assess Strata Critical's ability to earn profits and add value for shareholders.Net Loss | First Reported 2019-09-30 | Previous Quarter -3.7 M | Current Value 57.4 M | Quarterly Volatility 15.5 M |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.14 | 0.21 |
|
|
For Strata Critical profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Strata Critical Medical to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Strata Critical utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Strata Critical's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Strata Critical over time as well as its relative position and ranking within its peers.
Strata Critical Earnings per Share Projection vs Actual
The next projected EPS of Strata Critical is estimated to be 0.02 with future projections ranging from a low of 0.02 to a high of 0.02. Strata Critical's most recent 12-month trailing earnings per share (EPS TTM) is at -0.24. Please be aware that the consensus of earnings estimates for Strata Critical Medical is based on EPS before non-recurring items and includes expenses related to employee stock options.Strata Critical Earnings Estimation Breakdown
The calculation of Strata Critical's earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Strata Critical is estimated to be 0.02 with the future projection ranging from a low of 0.02 to a high of 0.02. Please be aware that this consensus of annual earnings estimates for Strata Critical Medical is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
0.02 Lowest | Expected EPS | 0.02 Highest |
Strata Critical Earnings Projection Consensus
Suppose the current estimates of Strata Critical's value are higher than the current market price of the Strata Critical stock. In this case, investors may conclude that Strata Critical is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Strata Critical's stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2026 | Current EPS (TTM) | |
| 2 | 50.0% | 0.0 | 0.02 | -0.24 |
Strata Critical Ownership Allocation
Strata Critical Medical shows a total of 85.13 Million outstanding shares. Over half of Strata Critical's outstanding shares are owned by institutional holders. These institutional holders are typically referred to as corporate investors that take positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.Strata Critical Profitability Analysis
The company reported the previous year's revenue of 248.69 M. Net Loss for the year was (27.31 M) with profit before overhead, payroll, taxes, and interest of 13.17 M.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Strata Critical's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Strata Critical and how it compares across the competition.
About Strata Critical Valuation
The stock valuation mechanism determines Strata Critical's current worth on a weekly basis. Our valuation model uses a comparative analysis of Strata Critical. We calculate exposure to Strata Critical's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Strata Critical's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 67.8 M | 71.1 M | |
| Pretax Profit Margin | (0.10) | (0.10) | |
| Operating Profit Margin | (0.12) | (0.13) | |
| Net Loss | (0.10) | (0.10) | |
| Gross Profit Margin | 0.21 | 0.14 |
Strata Critical Current Valuation Indicators
Valuation refers to the process of determining the present value of Strata Critical Medical and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Strata we look at many different elements of the entity such as Strata's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Strata Critical, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Strata Critical's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Strata Critical's worth.Complementary Tools for Strata Stock analysis
When running Strata Critical's price analysis, check to measure Strata Critical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Strata Critical is operating at the current time. Most of Strata Critical's value examination focuses on studying past and present price action to predict the probability of Strata Critical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Strata Critical's price. Additionally, you may evaluate how the addition of Strata Critical to your portfolios can decrease your overall portfolio volatility.
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Transaction History View history of all your transactions and understand their impact on performance |